secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0000719135-24-000008
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical announces Renuvion study shows significantly fewer adverse events vs InMode RF
--------------------------------------------------------------------------------

- Retrospective study of 450+ patients: 229 Renuvion vs 236 InMode Bipolar RF; statistically fewer adverse events (p<.0001).
- Adverse events included burns, hematoma, hypertrophic scar, and seroma; Renuvion group had significantly less.
- Renuvion featured in three educational sessions at AACS 40th Annual Scientific Meeting, Feb 22-24, 2024.
- Dr. Michael Kluska presents the study; CEO Charlie Goodwin highlights expansion of clinical evidence supporting safety.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913524000008/0000719135-24-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913524000008/apyx-20240221.htm
  HTML page:      https://secwatch.observer/filing/0000719135-24-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer